Misoprostol for abortion at 9-12 weeks' gestation in adolescents

被引:8
作者
Carbonell, JLL
Velazco, A
Varela, L
Tanda, R
Sánchez, C
Barambio, S
Chami, S
Valero, F
Aragón, S
Marí, J
机构
[1] Clin Mediterrania Med, Valencia 46007, Castello, Spain
[2] Hosp Gineco Obstet Eusebio Hernandez Maternidad O, Havana, Cuba
[3] Clin Tutor Med, Barcelona, Spain
[4] Clin Isadora, Madrid, Spain
[5] Clin Delta Med, Murcia, Spain
关键词
misoprostol; abortion; adolescents;
D O I
10.1080/713604177
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The objectives of the present clinical study were to evaluate the safety and efficacy of misoprostol (Cytotec(R)), self-administered into the vagina for medical abortion, in adolescents under 18 years of age. A group of 150 adolescents with gestations between 63 and 84 days, with previous written consent from the patient and parents or guardians, received 800 mug of vaginal misoprostol every 24 h, up to a maximum of three main doses, for abortion. Outcomes assessed included successful abortion (complete abortion without surgery), side-effects, decrease in hemoglobin, mean time of vaginal bleeding, mean expulsion time and mean time for the return of menses. Complete abortion occurred in 126/150 (84.0%, 95% confidence interval 77-89) patients. The frequencies of nausea and vomiting were statistically significantly higher when compared to those obtained for adult females. Vaginal bleeding lasted for 13.2 +/- 3.8 days (median 13 days, range 1-22 days). The mean expulsion time was 8.0 +/- 3.4 h (median 8 h, range 1-14 h) for all subjects who aborted after the first misoprostol dose. The mean drop in hemoglobin was statistically significant (p = 0.001), but without clinical relevance. From the high abortion rate obtained, we concluded that misoprostol alone is a valid method for terminating unwanted pregnancies at 10-13 weeks' gestation in adolescents under 18 years of age in the absence of mifepristone.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 16 条
[1]   Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol [J].
Ashok, PW ;
Flett, GM ;
Templeton, A .
LANCET, 1998, 352 (9127) :542-543
[2]  
Carbonell J L, 1998, Eur J Contracept Reprod Health Care, V3, P93
[3]  
Carbonell J L, 1997, Eur J Contracept Reprod Health Care, V2, P181
[4]   Oral methotrexate and vaginal misoprostol for early abortion [J].
Carbonell, JLL ;
Varela, L ;
Velazco, A ;
Cabezas, E ;
Fernández, C ;
Sánchez, C .
CONTRACEPTION, 1998, 57 (02) :83-88
[5]   The use of misoprostol for termination of early pregnancy [J].
Carbonell, JLL ;
Varela, L ;
Velazco, A ;
Fernandez, C .
CONTRACEPTION, 1997, 55 (03) :165-168
[6]  
CARBONELL JLL, 1999, EUR J CONTRACEP REPR, V4, P1
[7]  
Creinin M D, 1999, J Pediatr Adolesc Gynecol, V12, P71, DOI 10.1016/S1083-3188(00)86630-9
[8]   A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion [J].
Creinin, MD ;
Carbonell, JLL ;
Schwartz, JL ;
Varela, L ;
Tanda, R .
CONTRACEPTION, 1999, 59 (01) :11-16
[10]   Medical termination of pregnancy at 63 to 83 days gestation [J].
Gouk, EV ;
Lincoln, K ;
Khair, A ;
Haslock, J ;
Knight, J ;
Cruickshank, DJ .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (06) :535-539